首頁 > 市場調查報告書 > 醫療設備

生技設備

市場調查報告書

商品編碼

1624374

全球基於 NGS 的 RNA 定序市場規模（按產品/服務、技術、應用、最終用戶、地區、範圍和預測）

Global NGS-based RNA-seq Market Size By Product And Service, By Technology, By Application, By End-User, By Geographic Scope And Forecast

出版日期: 2024年08月11日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

基於NGS的RNA定序市場規模及預測

基於 NGS 的 RNA-Seq 市場規模預計在 2023 年價值 31.7 億美元，並在 2031 年達到 128.1 億美元，從 2024 年到 2031 年的複合年增長率為 19.05%。基於NGS的RNA-Seq（基於次世代定序的RNA定序）是一種可以徹底研究和量化樣本總RNA含量的技術。基於NGS 的RNA-Seq 將RNA 轉換為cDNA 片段庫，然後使用高通量定序方法讀取這些片段，以發現已知和新的轉錄物、量化基因表現水平並識別可變剪接事件。諸如發現之類的見解。基於NGS的RNA-Seq有許多應用，包括基礎研究和臨床診斷。在研究中，它們用於研究不同條件下的基因表現模式，以瞭解疾病的分子原因並確定未來的治療目標。

此外，它們還可用於傳染病研究，用於檢測和表徵病原體，並可用於農業中農作物和牲畜的基因改良。

全球基於 NGS 的 RNA 定序市場動態

影響基於 NGS 的 RNA 定序市場的關鍵市場動態

主要市場驅動因子

技術進步：

次世代定序 (NGS) 技術的不斷改進，提高了 RNA 定序的速度和準確性，同時顯著降低了其成本。這使得基於NGS的RNA-Seq更易於獲取並更適合研究和臨床診斷，從而促進市場成長。

個人化醫療需求不斷成長：

基於NGS的RNA-Seq對於瞭解疾病的遺傳基礎至關重要，這對於個人化治療的開發必不可少。對個人化治療方法的日益重視推動了臨床實踐對 RNA-Seq 的需求。

增加基因研究：

基因研究正在興起，特別是在癌症、神經病學和傳染病領域。基於NGS的RNA-Seq提供了對基因表現、調控和剪接的詳細見解，從而促進了這些研究領域的進步，並推動了市場的發展。

擴大在藥物發現與開發的應用：

基於NGS的RNA-Seq越來越多地用於藥物研究和開發，以尋找新的治療靶點並在基因組層面上更好地了解藥物反應。此應用是RNA-Seq市場的主要驅動力。

主要問題：

資料管理要求高：

基於NGS的RNA-Seq會產生大量數據，對數據儲存、管理和分析帶來重大障礙。需要先進的生物資訊工具和知識來處理和理解數據，這對小型實驗室和研究機構來說是一個重大障礙，限制了市場的成長。

樣品製備的複雜性：

基於NGS的RNA-Seq的樣本製備複雜且容易出錯，進而影響結果的準確性。這種複雜性需要訓練有素的工作人員，並增加了 RNA 定序工作的時間和成本，從而減少了市場需求。

成本限制：

即使 NGS 技術的成本正在下降，NGS 設備的初始成本以及試劑、維護和資料處理的持續成本對某些組織來說仍然是難以承受的。這阻礙了 RNA-Seq 在資源受限環境中的廣泛應用。

主要趨勢：

整合人工智慧與機器學習：

在基於 NGS 的 RNA-Seq 中使用 AI 和 ML 技術正變得越來越流行，以有效管理和分析大量數據。這些工具有助於識別基因表現數據中的複雜模式，進而改善研究成果和診斷準確性。

單細胞 RNA 定序（scRNA-Seq）的發展：

單細胞 RNA 定序的需求正在迅速增長，因為它能夠更精確地研究樣本中細胞的突變和功能。這一趨勢從根本上改變了我們對單細胞層面的生物學和疾病的理解。

多路復用與高通量技術：

多重和高通量定序技術使得同時分析多個樣本和基因成為可能。這將提高效率並降低每個樣本的成本，使得RNA-Seq更容易獲得並廣泛應用於研究和臨床診斷，有助於擴大市場。

擴展到臨床診斷：

在臨床診斷中使用基於 NGS 的 RNA-Seq 在基因組層面上發現和瞭解疾病的趨勢日益增長。這包括癌症診斷、傳染病和基因異常的應用，為更個人化和有效的治療鋪平了道路。

NGS-based RNA-seq Market size was valued at USD 3.17 Billion in 2023 and is projected to reach USD 12.81 Billion by 2031 , growing at a CAGR of 19.05% from 2024 to 2031. NGS-based RNA-seq (Next-Generation Sequencing-based RNA sequencing) is a technology that enables a thorough investigation and quantification of a sample's total RNA content. NGS-based RNA-seq converts RNA into a library of cDNA fragments that are then read using high-throughput sequencing methods, which can discover known and novel transcripts, quantify gene expression levels, and uncover alternative splicing events, among other findings. NGS-based RNA-seq has many applications, including basic research and clinical diagnostics. In research, it is used to investigate gene expression patterns under various situations, gain a molecular understanding of disease causes, and find prospective treatment targets

Furthermore, it is useful in the research of infectious illnesses by allowing for pathogen detection and characterization, as well as in agriculture for crop and livestock genetic improvement.

Global NGS-based RNA-seq Market Dynamics

The key market dynamics that are shaping the NGS-based RNA-seq Market include:

Key Market Drivers

Technological Advancements:

The constant improvement of Next-Generation Sequencing (NGS) technologies has greatly decreased costs while increasing the speed and accuracy of RNA sequencing. This makes NGS-based RNA-seq more accessible and desirable for research and clinical diagnostics, resulting in increased market growth.

Increased Demand for Personalized Medicine:

NGS-based RNA-seq has become crucial for understanding the genetic basis of diseases, which is required for the development of personalized therapy. The rising emphasis on individualized treatment approaches drives up the need for RNA-seq in clinical settings.

Rise in Genetic Research:

There is an increase in genetic research, particularly in cancer, neurology, and infectious disorders. NGS-based RNA-seq gives detailed insights into gene expression, regulation, and splicing, allowing for advances in these study domains and propelling the market.

Expanding Applications in Drug Discovery and Development:

NGS-based RNA-seq is increasingly being utilized in drug research and development to find new therapeutic targets and better understand drug responses at the genomic level. This application is a major driver of the RNA-seq market.

Key Challenges:

High Data Management Requirements:

NGS-based RNA-seq creates massive volumes of data, which presents substantial hurdles in data storage, management, and analysis. This need for sophisticated bioinformatics tools and knowledge to handle and understand data becomes a significant hurdle for smaller laboratories and research institutes, limiting market growth.

Complexity of Sample Preparation:

Sample preparation for NGS-based RNA-seq is complex and error-prone, affecting the accuracy of results. This complexity demands trained staff and increases the time and expense involved with RNA sequencing initiatives, reducing market demand.

Cost Constraints:

The original cost of NGS equipment and continuing expenses for reagents, maintenance, and data processing, even with NGS technology' declining costs, remain unaffordable for certain organizations. This hinders the widespread deployment of RNA-seq in resource-constrained environments.

Key Trends:

Integration of Artificial Intelligence and Machine Learning:

The use of AI and ML technologies in NGS-based RNA-seq is becoming increasingly popular for efficiently managing and analyzing large amounts of data. These tools help to identify complicated patterns in gene expression data for improving research outcomes and diagnosis accuracy.

Single-Cell RNA Sequencing (scRNA-seq) Growth:

Demand for single-cell RNA sequencing is quickly increasing since it allows for a more precise investigation of cellular variations and functions within a sample. This trend is fundamentally changing our understanding of biology and disease at the single-cell level.

Multiplexing and High-Throughput Technologies:

Multiplexing and high-throughput sequencing technologies have made it possible to analyze many samples or genes at the same time. This increases efficiency and lowers the cost per sample, making RNA-seq more accessible and widely used in research and clinical diagnoses, promoting market expansion.

Expansion into Clinical Diagnostics:

There is an increasing trend of using NGS-based RNA-seq in clinical diagnostics to discover and understand disorders at the genomic level. This includes applications in cancer diagnoses, infectious diseases, and genetic abnormalities, paving the path for more personalized and effective therapies.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global NGS-based RNA-seq Market Regional Analysis

Here is a more detailed regional analysis of the NGS-based RNA-seq Market:

North America:

According to Verified Market Research, North America is estimated to dominate in NGS-based RNA-seq Market over the forecast period. North America, particularly the United States, has a strong research infrastructure, including multiple top universities, research organizations, and biotech companies. This climate promotes innovation and rapid adoption of NGS-based RNA-seq technologies, allowing the region to dominate the market

Significant public and private investment in the healthcare and biotechnology industries in North America enables advanced research, development, and application of NGS-based RNA-seq. This financial support speeds up technical breakthroughs and their implementation in healthcare settings.

Personalized medicine is becoming increasingly popular in North America, to tailor medical treatments to individual genetic profiles. NGS-based RNA-seq is critical for understanding genetic variants, thereby, driving its use in both research and clinical diagnostics throughout the region.

Furthermore, the regulatory climate in North America, particularly in the United States, fosters the development and application of NGS-based technologies, thanks to the FDA's proactive approach to genomic and precision medicine. This supporting policy framework shortens the path to market for innovative RNA-seq applications and developments.

Asia Pacific:

Asia Pacific is estimated to grow at the highest CAGR within the NGS-based RNA-seq Market during the forecast period. The region's healthcare sector is expanding rapidly, supported by increased investment and government measures to improve healthcare infrastructure. This expansion encourages the use of modern technologies such as NGS-based RNA-seq in diagnosis and research.

Precision medicine is becoming increasingly important in Asia Pacific countries, to provide patient-specific medicines based on genetic information. As a result of its importance in studying genetic variants, NGS-based RNA-seq is becoming increasingly popular.

The region is experiencing an increase in the prevalence of genetic abnormalities and cancer, necessitating the use of modern diagnostic technologies. NGS-based RNA-seq provides extensive insights into genetic information, allowing for early detection and personalized treatment regimens.

Furthermore, Asia-Pacific is emerging as a hub for biotechnology and pharmaceutical research and development. Governments and commercial organizations are increasing financing for genomics research, accelerating the expansion of NGS-based RNA-seq by providing critical resources for innovation and application in this field.

Europe:

Europe has a rich legacy of international collaborative research, which is encouraged by EU financing programs such as Horizon Europe. These efforts promote the use of NGS-based RNA-seq technologies in a variety of sectors, accelerating growth by pooling resources and expertise.

European countries are investing more in precision medicine, with national and regional initiatives aimed at incorporating genomic data into healthcare. NGS-based RNA-seq is critical for these activities, resulting in increased application in both research and clinical diagnoses.

The most recent genomics technology advancements are being quickly adopted by the European market. This includes NGS-based RNA-seq, which is growing and becoming more accessible across the region because of advances in sequencing efficiency, data processing, and cost reductions, driving market adoption.

Furthermore, the biotech and pharmaceutical industries in Europe are expanding rapidly, with an emphasis on medication discovery and development using genomic data. NGS-based RNA-seq is critical for discovering new therapeutic targets and understanding disease mechanisms, driving its development in these industries.

Global NGS-based RNA-seq Market: Segmentation Analysis

The NGS-based RNA-seq Market is Segmented based on Product & Service, Technology, Application, End-user, And Geography.

NGS-based RNA-seq Market, By Product & Service

Sample Preparation Products
Sequencing Platforms and Consumables
Sequencing Services
Data Analysis, Storage and Management

Based on Product & Service, the market is segmented into Sample Preparation Products, Sequencing Platforms and Consumables, Sequencing Services, and Data Analysis, Storage & Management. The sequencing platforms and consumables segment is estimated to dominate the NGS-based RNA-seq Market due to the critical function these products play throughout the sequencing process. Sequencing platforms and consumables are critical components of RNA sequencing because they have a direct impact on the efficiency, accuracy, and throughput of the sequencing procedures. The high costs of these platforms, along with the continuous requirement for consumables, ensure that this category receives a sizable share of market income.

NGS-based RNA-seq Market, By Technology

Sequencing by Synthesis (SBS)
Ion Semiconductor Sequencing
Single-molecule Real-time Sequencing
Nanopore Sequencing

Based on Technology, the market is segmented into Sequencing by Synthesis (SBS), Ion Semiconductor Sequencing, Single-molecule Real-time Sequencing, and Nanopore Sequencing. The sequencing by synthesis (SBS) segment is estimated to grow at the highest CAGR in the NGS-based RNA-seq Market due to its widespread use in academic research and clinical diagnostics due to its high throughput, precision, and cost-effectiveness when compared with other sequencing methods. SBS, as demonstrated by Illumina's sequencing platforms, has established the gold standard in NGS because it delivers a consistent balance of read length and sequencing depth, making it ideal for a wide range of applications, including transcriptome profiling and whole-genome sequencing.

NGS-based RNA-seq Market, By Application

Expression Profiling Analysis
Small RNA Sequencing
De Novo Transcriptome Assembly
Variant Calling and Transcriptome Epigenetics

Based on Application, the market is segmented into Expression Profiling Analysis, Small RNA Sequencing, De Novo Transcriptome Assembly, and Variant Calling & Transcriptome Epigenetics. The expression profiling analysis segment is estimated to exhibit the highest growth within the market over the forecast period due to the crucial role that expression profiling plays in understanding gene function, regulation, and the genetic basis of illness. Expression profiling analysis using NGS-based RNA-seq offers unprecedented depth and breadth in assessing the expression levels of thousands of genes at the same time, providing insights into the molecular signatures of distinct cells and tissues under varied settings.

NGS-based RNA-seq Market, By End-User

Research and Academia
Hospitals and Clinics
Pharmaceutical and Biotechnology Companies
Others

Based on End-User, the market is segmented into Research and Academia, Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, and Others. The research and academia segment is estimated to grow at the highest CAGR in the market over the forecast period owing to the widespread use of NGS-based RNA sequencing in basic and applied research to get an unprecedented understanding of genomic expressions, variants, and functions. Globally, academic and research organizations make significant investments in genomic research, using RNA-seq technology to investigate difficult biological problems, disease processes, and evolutionary studies.

Key Players

The "Global NGS-based RNA-seq Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are
Illumina, Thermo Fisher Scientific, Agilent Technologies, F. Hoffmann-La Roche, QIAGEN, PerkinElmer, Pacific Biosciences of California, Oxford Nanopore Technologies, Novogene Co., BGI, Macrogen, GENEWIZ, Eurofins Genomics, Twist Bioscience Corporation, MGI Tech Co., Paragon Genomics, NanoString Technologies, Lexogen, and Singular Genomics Systems.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

NGS-based RNA-seq Market Recent Developments
In February 2024, Illumina announced its new "NovaSeq X Plus" sequencing equipment, which promises quicker run times and increased throughput for single-cell RNA-seq applications. This technology is intended to be especially useful for researchers investigating intricate biological processes at the cellular level.
In February 2024, BGI and Berry Genomics announced a collaboration to create an AI-powered platform for analyzing RNA-seq data. This platform is intended to increase the accuracy and efficiency of RNA-seq data analysis, resulting in faster and more precise diagnoses and treatment strategies.
In February 2024, NanoString Technologies received FDA approval for its GeoMx NGS Targeted Assay, a next-generation sequencing (NGS) solution for targeted gene expression analysis. This approval opens up new avenues for applying NGS technology in clinical settings.
In February 2024, 10x Genomics and Sema4 announced a collaboration to develop and commercialize spatial transcriptomics technologies. This cooperation seeks to combine 10x Genomics' spatial biology knowledge with Sema4's artificial intelligence and machine learning skills, resulting in advanced solutions for analyzing the spatial distribution of RNA in tissues.

1 INTRODUCTION OF GLOBAL NGS-BASED RNA-SEQ MARKET

1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL NGS-BASED RNA-SEQ MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis
4.5 Regulatory Framework

5 GLOBAL NGS-BASED RNA-SEQ MARKET, BY PRODUCT & SERVICE

5.1 Overview
5.2 Sample Preparation Products
5.3 Sequencing Platforms and Consumables
5.4 Sequencing Services
5.5 Data Analysis, Storage and Management

6 GLOBAL NGS-BASED RNA-SEQ MARKET, BY END-USER

6.1 Overview
6.2 Research and Academia
6.3 Hospitals and Clinics
6.4 Pharmaceutical and Biotechnology Companies
6.5 Others

7 GLOBAL NGS-BASED RNA-SEQ MARKET, BY APPLICATION

7.1 Overview
7.2 Expression Profiling Analysis
7.3 Small RNA Sequencing
7.4 De Novo Transcriptome Assembly
7.5 Variant Calling and Transcriptome Epigenetics

8 GLOBAL NGS-BASED RNA-SEQ MARKET, BY TECHNOLOGY

8.1 Overview
8.2 Sequencing by Synthesis (SBS)
8.3 Ion Semiconductor Sequencing
8.4 Single-molecule Real-time Sequencing
8.5 Nanopore Sequencing

9 GLOBAL NGS-BASED RNA-SEQ MARKET, BY GEOGRAPHY

9.1 Overview
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
- 9.2.3 Mexico
9.3 Europe
- 9.3.1 Germany
- 9.3.2 U.K.
- 9.3.3 France
- 9.3.4 Rest of Europe
9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Argentina
9.6 Rest of the World

10 GLOBAL NGS-BASED RNA-SEQ MARKET COMPETITIVE LANDSCAPE

10.1 Overview
10.2 Company Market Share
10.3 Vendor Landscape
10.4 Key Development Strategies

11 COMPANY PROFILES

11.1 Illumina
- 11.1.1 Overview
- 11.1.2 Financial Performance
- 11.1.3 Product Outlook
- 11.1.4 Key Developments
11.2 Thermo Fisher Scientific
- 11.2.1 Overview
- 11.2.2 Financial Performance
- 11.2.3 Product Outlook
- 11.2.4 Key Developments
11.3 Agilent Technologies
- 11.3.1 Overview
- 11.3.2 Financial Performance
- 11.3.3 Product Outlook
- 11.3.4 Key Developments
11.4 F. Hoffmann-La Roche
- 11.4.1 Overview
- 11.4.2 Financial Performance
- 11.4.3 Product Outlook
- 11.4.4 Key Developments
11.5 QIAGEN
- 11.5.1 Overview
- 11.5.2 Financial Performance
- 11.5.3 Product Outlook
- 11.5.4 Key Developments
11.6 PerkinElmer
- 11.6.1 Overview
- 11.6.2 Financial Performance
- 11.6.3 Product Outlook
- 11.6.4 Key Developments
11.7 Pacific Biosciences of California
- 11.7.1 Overview
- 11.7.2 Financial Performance
- 11.7.3 Product Outlook
- 11.7.4 Key Developments
11.8 Oxford Nanopore Technologies
- 11.8.1 Overview
- 11.8.2 Financial Performance
- 11.8.3 Product Outlook
- 11.8.4 Key Developments
11.9 Novogene Co.
- 11.9.1 Overview
- 11.9.2 Financial Performance
- 11.9.3 Product Outlook
- 11.9.4 Key Developments
11.10 BGI
- 11.10.1 Overview
- 11.10.2 Financial Performance
- 11.10.3 Product Outlook
- 11.10.4 Key Developments